骨骼与癌症：骨肿瘤学
Bone and cancer: the osteoncology.
作者信息
Ibrahim Toni, Mercatali Laura, Amadori Dino
机构信息
Osteoncology and Rare Tumors Center, IRCCS Meldola, Italy.
出版信息
Clin Cases Miner Bone Metab. 2013 May;10(2):121-3.
Abstract
In recent years clinicians have witnessed a radical change in the relationship between bone and cancer, with in particular an increase in bone metastases incidence due to an improvement of patients survival. Bone metastases are responsible for the high morbidity in cancer patients with a strong clinical impact. For all these reasons, efforts have been directed to this important field with the foundation of the osteoncology, a new scientific and clinical branch involved in the management of patients with bone cancer disease, including primary bone tumors and bone metastases. Another innovative and important osteoncology topic is the Cancer Treatment Induced Bone Loss (CTIBL) that is mainly caused by antitumoral treatment with bone resorption induction. The diagnostic and therapeutic options are described briefly in order to highlight the importance of the multidisciplinary approach in this new field.
摘要
近年来，临床医生见证了骨骼与癌症之间关系的彻底改变，尤其是由于患者生存率的提高，骨转移的发生率有所增加。骨转移是癌症患者高发病率的原因，具有很强的临床影响。出于所有这些原因，人们通过建立骨肿瘤学，将努力方向指向了这一重要领域。骨肿瘤学是一个新的科学和临床分支，涉及骨癌疾病患者的管理，包括原发性骨肿瘤和骨转移。另一个创新且重要的骨肿瘤学主题是癌症治疗引起的骨丢失（CTIBL），其主要由诱导骨吸收的抗肿瘤治疗引起。简要描述了诊断和治疗选择，以突出这一新领域中多学科方法的重要性。
相似文献
1
Bone and cancer: the osteoncology.
Clin Cases Miner Bone Metab. 2013 May;10(2):121-3.
2
Ten-year experience of the multidisciplinary Osteoncology Center.
Support Care Cancer. 2019 Sep;27(9):3395-3402. doi: 10.1007/s00520-019-4635-5. Epub 2019 Jan 16.
3
[Cancer Treatment-Induced Bone Loss(CTIBL)].
Gan To Kagaku Ryoho. 2018 Dec;45(12):1685-1689.
4
Cancer treatment-induced bone loss in patients with breast or prostate cancer.
Oncol Nurs Forum. 2005 May 10;32(3):589-603. doi: 10.1188/05.onf.589-603.
5
Cancer-treatment-induced bone loss, part 2.
Am J Health Syst Pharm. 2006 Mar 15;63(6):534-46. doi: 10.2146/ajhp050045.p2.
6
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
Oncologist. 2008 Feb;13(2):187-95. doi: 10.1634/theoncologist.2007-0152.
7
Cancer-treatment-induced bone loss, part 1.
Am J Health Syst Pharm. 2006 Mar 1;63(5):419-30. doi: 10.2146/ajhp050045.p1.
8
Emerging drugs for the management of cancer treatment induced bone loss.
Expert Opin Emerg Drugs. 2010 Jun;15(2):323-42. doi: 10.1517/14728211003631385.
9
Moving into the future: treatment of bone metastases and beyond.
Cancer Treat Rev. 2005;31 Suppl 3:9-18. doi: 10.1016/j.ctrv.2005.09.003. Epub 2005 Oct 24.
10
Bone Health in Men with Prostate Cancer: Review Article.
Curr Osteoporos Rep. 2019 Dec;17(6):527-537. doi: 10.1007/s11914-019-00536-8.
引用本文的文献
1
Exploring bone-tumor interactions through 3D models: Implications for primary and metastatic cancers.
J Bone Oncol. 2025 Jun 17;53:100698. doi: 10.1016/j.jbo.2025.100698. eCollection 2025 Aug.
2
Predicting Osteoporosis in Elderly Cancer Patients Using the Modified Glasgow Prognostic Index.
Cancer Control. 2025 Jan-Dec;32:10732748251337601. doi: 10.1177/10732748251337601. Epub 2025 Apr 23.
3
Advancements in mesoporous bioactive glasses for effective bone cancer therapy: Recent developments and future perspectives.
Biomater Biosyst. 2025 Feb 15;17:100108. doi: 10.1016/j.bbiosy.2025.100108. eCollection 2025 Mar.
4
Bone scintigraphy based on deep learning model and modified growth optimizer.
Sci Rep. 2024 Oct 27;14(1):25627. doi: 10.1038/s41598-024-73991-8.
5
Evaluation of Changes in Activities of Daily Living and Quality of Life of Patients with Bone Metastasis Who Underwent Conservative Therapy through Bone Metastasis Cancer Boards.
Medicina (Kaunas). 2024 May 29;60(6):906. doi: 10.3390/medicina60060906.
6
A comparative analysis of CNN-based deep learning architectures for early diagnosis of bone cancer using CT images.
Sci Rep. 2024 Jan 25;14(1):2144. doi: 10.1038/s41598-024-52719-8.
7
Optimal timing for local ablative treatment of bone oligometastases in non-small cell lung cancer.
J Bone Oncol. 2023 Aug 2;42:100496. doi: 10.1016/j.jbo.2023.100496. eCollection 2023 Oct.
8
Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation.
Pharmaceutics. 2023 Jun 20;15(6):1772. doi: 10.3390/pharmaceutics15061772.
9
Pathological fracture due to primary bone lymphoma in a patient with a history of prostate cancer: A case report and review of literature.
Front Oncol. 2023 Mar 16;13:1100559. doi: 10.3389/fonc.2023.1100559. eCollection 2023.
10
Risk of Myelopathy Following Second Local Treatment after Initial Irradiation of Spine Metastasis.
Diagnostics (Basel). 2023 Jan 4;13(2):175. doi: 10.3390/diagnostics13020175.
本文引用的文献
1
Metastatic bone disease in the era of bone-targeted therapy: clinical impact.
Tumori. 2013 Jan-Feb;99(1):1-9. doi: 10.1177/030089161309900101.
2
miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis.
Nat Cell Biol. 2013 Mar;15(3):284-94. doi: 10.1038/ncb2690. Epub 2013 Feb 10.
3
Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2.
Nat Cell Biol. 2012 Nov;14(11):1212-22. doi: 10.1038/ncb2607. Epub 2012 Oct 21.
4
Antiresorptive therapies in oncology and their effects on cancer progression.
Cancer Treat Rev. 2012 Oct;38(6):776-86. doi: 10.1016/j.ctrv.2012.02.002. Epub 2012 Feb 26.
5
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.
Lancet. 2012 Jan 7;379(9810):39-46. doi: 10.1016/S0140-6736(11)61226-9. Epub 2011 Nov 15.
6
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.
Nat Med. 2011 Aug 7;17(9):1101-8. doi: 10.1038/nm.2401.
7
Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.
Clin Breast Cancer. 2011 Dec;11(6):369-75. doi: 10.1016/j.clbc.2011.05.001. Epub 2011 Jul 20.
8
The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study.
Oncology. 2011;80(3-4):225-31. doi: 10.1159/000327585. Epub 2011 Jul 5.
9
Pathogenesis of osteoblastic bone metastases from prostate cancer.
Cancer. 2010 Mar 15;116(6):1406-18. doi: 10.1002/cncr.24896.
10
Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model.
Tumori. 2009 May-Jun;95(3):291-7. doi: 10.1177/030089160909500304.
Zotero 插件